Scholarlink

<p>Extraskeletal myxoid chondrosarcoma (EMC) is a rare mesenchymal neoplasm of uncertain differentiation associating with diagnostic <i>NR4A3</i> gene rearrangements. An unusual case of EMC harboring the novel <i>HSPA8</i>::<i>NR4A2</i> gene fusion and neuroendocrine phenotype is described. The tumor exhibited a lobular architecture, myxoid stroma, and epithelioid tumor cells with a complete neuroendocrine phenotype by specific immunohistochemistry and transmission electron microscopy. The lesions showed a low tumor mutational burden (1.9 muts/Mb), a microsatellite stable status, no cancer driver gene mutations, no canonical <i>NR4A3</i> fusion and low copy number variation. A novel in-frame fusion between <i>HSPA8</i> (exon 2) and <i>NR4A2</i> (exon 3) was identified by RNA-sequencing and methylation analysis placed the lesion into the EMC class (0.99 score). Transcriptome cluster comparative analysis placed its expression profile close to&#xa0;pancreas neuroendocrine tumors. This case suggests <i>NR4A2</i> as a functionally substitute for <i>NR4A3</i> in tumorigenesis and a neuroendocrine lineage differentiation for a subset of EMC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Novel HSPA8-NR4A2 rearrangement in extraskeletal myxoid chondrosarcoma: a sarcoma mimicker of neuroendocrine neoplasia

  • 期刊论文

  • 发表日期：

    2025年11月28日

查看全文
  • Sabina Barresi,
  • Roberto Passa,
  • Silvia Vallese,
  • Evelina Miele,
  • Sara Patrizi,
  • Carla Rabitti,
  • Bruno Vincenzi,
  • Sergio Valeri,
  • Francesca Diomedi Camassei,
  • Angelo Minucci,
  • Marco Pieraccioli,
  • Claudio Sette,
  • Rita Alaggio,
  • Guido Rindi

摘要

Extraskeletal myxoid chondrosarcoma (EMC) is a rare mesenchymal neoplasm of uncertain differentiation associating with diagnostic NR4A3 gene rearrangements. An unusual case of EMC harboring the novel HSPA8::NR4A2 gene fusion and neuroendocrine phenotype is described. The tumor exhibited a lobular architecture, myxoid stroma, and epithelioid tumor cells with a complete neuroendocrine phenotype by specific immunohistochemistry and transmission electron microscopy. The lesions showed a low tumor mutational burden (1.9 muts/Mb), a microsatellite stable status, no cancer driver gene mutations, no canonical NR4A3 fusion and low copy number variation. A novel in-frame fusion between HSPA8 (exon 2) and NR4A2 (exon 3) was identified by RNA-sequencing and methylation analysis placed the lesion into the EMC class (0.99 score). Transcriptome cluster comparative analysis placed its expression profile close to pancreas neuroendocrine tumors. This case suggests NR4A2 as a functionally substitute for NR4A3 in tumorigenesis and a neuroendocrine lineage differentiation for a subset of EMC.